Molecular mechanisms behind presumed reduced ovarian reserve and embryo competence in BRCA1/2-mutation carriers in IVF/PGD

Withdrawn

• Conditions: ovarian reserve; reduced oocyte availability; 10083624; 10006291; 10033283

• Registration Number: NL-OMON38833
• Lead Sponsor: Medisch Universitair Ziekenhuis Maastricht

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Withdrawn
• Sex: Not specified
• Target Recruitment: 245

Inclusion Criteria

- IVF/PGD treatment for a BRCA1/2 mutation, both female and male mutation carriers
- IVF/PGD treatment because of an autosomal dominant genetic disorder transmitted by the male
- IVF treatment, including ICSI, for male subfertility

Exclusion Criteria

- Previous diagnosis of female subfertility in controls
- Known hereditary disease other than due to BRCA1/2-mutations in the female
- Known history of a malignancy in the female
- History of cancer treatment in the female
- Non-Dutch couples, not able to understand the patient information to give
informed consent properly

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>a) determine the presence of apoptosis, DNA damage, impaired spindle formation<br /><br>or other cell division defects present in the studied biological samples<br /><br>compared to controls. b) exploration and identification of the molecular<br /><br>pathways associated with reduced ovarian reserve and oocyte/embryo competence<br /><br>in BRCA1/2-mutation carriers. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>NA</p><br>